Hydrochlorothiazide

Hydrochlorothiazide
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Hydrochlorothiazide is a thiazide diuretic that is FDA approved for the {{{indicationType}}} of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. Common adverse reactions include hypotension, phototoxicity, and vertigo.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Hypertension

• Dosing Information

• 12.5 mg once daily whether given alone or in combination with other antihypertensives.
• Total daily doses greater than 50 mg are not recommended.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Hydrochlorothiazide in adult patients.

Non–Guideline-Supported Use

Hypercalciuria

• Dosing Information

• 25–50 mg/day

Osteoporosis

• Dosing Information

• 12.5–25 mg/day

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Hydrochlorothiazide in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Hydrochlorothiazide in pediatric patients.

Non–Guideline-Supported Use

Hypercalciuria

• Dosing Information

• 0.5–2 mg/kg/day

Bronchopulmonary Dysplasia of Newborn

• Dosing Information

• 1 mg/kd/day

Contraindications

• Anuria
• Hypersensitivity to this product or other sulfonamide derived drugs

Warnings

• Acute Myopia and Secondary Angle-Closure Glaucoma

• Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.

• Diabetes and Hypoglycemia

• Latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose.

• Renal Disease

• Cumulative effects of the thiazides may develop in patients with impaired renal function. In such patients, thiazides may precipitate azotemia.

Precautions

• Electrolyte and Fluid Balance Status

• In published studies, clinically significant hypokalemia has been consistently less common in patients who received 12.5 mg of hydrochlorothiazide than in patients who received higher doses. Nevertheless, periodic determination of serum electrolytes should be performed in patients who may be at risk for the development of hypokalemia. Patients should be observed for signs of fluid or electrolyte disturbances, i.e., hyponatremia, hypochloremic alkalosis, and hypokalemia and hypomagnesemia.
• Warning signs or symptoms of fluid and electrolyte imbalance include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.
• Hypokalemia may develop, especially with brisk diuresis when severe cirrhosis is present, during concomitant use of corticosteroid or adrenocorticotropic hormone (ACTH) or after prolonged therapy. Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia and hypomagnesemia can provoke ventricular arrhythmias or sensitize or exaggerate the response of the heart to the toxic effects of digitalis. Hypokalemia may be avoided or treated by potassium supplementation or increased intake of potassium rich foods.
• Dilutional hyponatremia is life-threatening and may occur in edematous patients in hot weather; appropriate therapy is water restriction rather than salt administration, except in rare instances when the hyponatremia is life-threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

• Hyperuricemia

• Hyperuricemia or acute gout may be precipitated in certain patients receiving thiazide diuretics.

• Impaired Hepatic Function

• Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate hepatic coma in patients with severe liver disease.

• Parathyroid Disease

• Calcium excretion is decreased by thiazides, and pathologic changes in the parathyroid glands, with hypercalcemia and hypophosphatemia, have been observed in a few patients on prolonged thiazide therapy.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Hydrochlorothiazide in the drug label.

Postmarketing Experience

• Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.
• The adverse reactions associated with hydrochlorothiazide have been shown to be dose related. In controlled clinical trials, the adverse events reported with doses of 12.5 mg hydrochlorothiazide once daily were comparable to placebo. The following adverse reactions have been reported for doses of hydrochlorothiazide 25 mg and greater and, within each category, are listed in the order of decreasing severity.

Body as a Whole

Weakness

Neurologic

Vertigo, paresthesia, dizziness, headache, restlessness.

Cardiovascular

Hematologic

Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia.

Gastrointestinal

Pancreatitis, jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis, cramping, constipation, gastric irritation, nausea, anorexia.

Hypersensitivity

Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash, purpura.

Metabolic

Electrolyte imbalance, hyperglycemia, glycosuria, hyperuricemia.

Musculoskeletal

Muscle spasm.

Renal

Renal failure, renal dysfunction, interstitial nephritis.

Skin

Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia.

Special Senses

Transient blurred vision, xanthopsia.

Urogenital

Impotence.

Drug Interactions

• Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur.
• Antidiabetic drugs - (oral agents and insulin) dosage adjustment of the antidiabetic drug may be required.
• Other antihypertensive drugs - additive effect or potentiation.
• Cholestyramine and colestipol resins - Cholestyramine and colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.
• Corticosteroid, ACTH – intensified electrolyte depletion, particularly hypokalemia.
• Pressor amines (e.g., norepinephrine) - possible decreased response to pressor amines but not sufficient to preclude their use.
• Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine) - possible increased responsiveness to the muscle relaxant.
• Lithium - generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and greatly increase the risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with MICROZIDE.
• Non-steroidal anti-inflammatory drugs - In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. When MICROZIDE and non-steroidal anti-inflammatory agents are used concomitantly, the patients should be observed closely to determine if the desired effect of the diuretic is obtained.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

• Pregnancy Category

Pregnancy Category (AUS):

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Hydrochlorothiazide in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Hydrochlorothiazide during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Hydrochlorothiazide with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Hydrochlorothiazide with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Hydrochlorothiazide with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Hydrochlorothiazide with respect to specific gender populations.

Race

There is no FDA guidance on the use of Hydrochlorothiazide with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Hydrochlorothiazide in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Hydrochlorothiazide in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Hydrochlorothiazide in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Hydrochlorothiazide in patients who are immunocompromised.

Administration and Monitoring

Administration

• Oral

• Intravenous

Monitoring

There is limited information regarding Monitoring of Hydrochlorothiazide in the drug label.

Condition1

• Description

IV Compatibility

There is limited information regarding IV Compatibility of Hydrochlorothiazide in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

• The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.
• The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in the mouse and rat.

Management

• In the event of overdosage, symptomatic and supportive measures should be employed. Emesis should be induced or gastric lavage performed. Correct dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures. If required, give oxygen or artificial respiration for respiratory impairment. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established.

Chronic Overdose

There is limited information regarding Chronic Overdose of Hydrochlorothiazide in the drug label.

Pharmacology

Hydrochlorothiazide
Systematic (IUPAC) name
6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide
Identifiers
CAS number	58-93-5
ATC code	C03AA03
PubChem	3639
DrugBank	DB00999
Chemical data
Formula	Template:OrganicBox atomTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox atomTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox
Mol. mass	297.74
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	Variably absorbed from GI tract. Bioavailability ~ 70%
Metabolism	does not undergo significant metabolism (>95% excreted unchanged in urine)
Half life	5.6–14.8 h
Excretion	Primarily excreted unchanged in urine
Therapeutic considerations
Pregnancy cat.	B (D if used to treat pregnancy-induced hypertension)
Legal status	Template:Unicode Prescription only
Routes	Oral (capsules, tablets, oral solution)

Mechanism of Action

Structure

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Hydrochlorothiazide in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Hydrochlorothiazide in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Hydrochlorothiazide in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Hydrochlorothiazide in the drug label.

Condition1

• Description

How Supplied

• MICROZIDE® (hydrochlorothiazide, USP) Capsules 12.5 mg are #4 Teal Opaque/Teal Opaque two piece hard gelatin capsules imprinted with MICROZIDE and 12.5 mg in black ink. They are supplied in bottles of 100 with child resistant closures (NDC 52544-622-01).
• Dispense in a tight, light-resistant container as defined in the USP.
• Keep out of reach of children.
• Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.] Protect from light, moisture, freezing, -20°C (-4°F). Keep container tightly closed.

Storage

There is limited information regarding Hydrochlorothiazide Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Hydrochlorothiazide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Hydrochlorothiazide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Hydrochlorothiazide in the drug label.

Precautions with Alcohol

• Alcohol-Hydrochlorothiazide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

• Microzide®

Look-Alike Drug Names

• Microzide® — Maxzide®

• Microzide® — Micronase®

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Page Name=Hydrochlorothiazide
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Hydrochlorothiazide
 |Label Name=Hydrochlorothiazide02.png

}}

{{#subobject:

 |Label Page=Hydrochlorothiazide
 |Label Name=Hydrochlorothiazide03.png

}}